US Merck Products
Showing 18 of 18 products
- #00857c(sugammadex) injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium), for intravenous use 
- #00857cISENTRESS® (raltegravir 400 mg) film-coated tablets, for oral use; chewable tablets, for oral use; oral suspension and ISENTRESS® HD (raltegravir 600 mg) film-coated tablets, for oral use 
- #00857cJANUMET® (sitagliptin and metformin HCI) 50/500 mg, 50/1000 mg tablets and JANUMET® XR (sitagliptin and metformin HCI extended-release) 50/500 mg, 50/1000 mg, 100/1000 mg tablets Before prescribing JANUMET or JANUMET XR, please read the Prescribing Information, including the Boxed Warning about lactic acidosis. 
- #00857cPIFELTRO® (doravirine 100 mg) tablets and DELSTRIGO® (doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg) tablets Before prescribing PIFELTRO, please read the accompanying Prescribing Information. The Patient Information also is available. Before prescribing DELSTRIGO, please read the accompanying Prescribing Information, including the Boxed Warning about posttreatment acute exacerbation of Hepatitis B. The Patient Information also is available. 
- #00857cPREVYMIS® (letermovir) 240 mg, 480 mg tablets / Injection 20 mg/mL / Oral pellets 20 mg, 120 mg per packet 
- #00857c(ertugliflozin and metformin HCI) 2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, 7.5 mg/1000 mg tablets Before prescribing SEGLUROMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis. 
- #00857c(tedizolid phosphate) 200 mg injection, for intravenous use; 200 mg tablet, for oral use 
- Before prescribing VERQUVO, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity. 
- Before prescribing WELIREG, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.